With a glutamate residue ima4nib inhibits protein

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: d block access to ATP • Type II inhibitors act on the inac4ve conforma4on of the enzyme • Type II inhibitors bind to the enzyme and stabilise the inac4ve conforma4on • Type II inhibitors are likely to be more selec4ve Type I inhibitors Gefi4nib, erlo4nib, SU11248 and seliciclib Type II inhibitors Ima4nib, lapa4nib, sorafenib and vatalanib Abl and Src Src, Abl, and Bcr- Abl hOp:// in- progress/5- 3/signaling/abl_kinase.html Ima4nib (Glivec or Gleevec) N Me H N N N H N O N Me N Notes • First protein kinase inhibitor to reach the market • Selec4ve inhibitor for a hybrid tyrosine kinase (Bcr- Abl) • Bcr- Abl is ac4ve in certain tumour cells Ima4nib (Glivec or Gleevec) Lead compound Pyrimidine H Anilino substituent N N N I • Phenylaminopyrimidine structure • Iden4fied by random screening of compound libraries • Originally iden4fied as a PKC inhibitor • PKC is a serine- threonine kinase Ima4nib (Glivec or Gleevec) Drug design Pyridine N H N N N N N I H N 3' N II H N N N IV (IC50 5 µM) H N Amide Increased inhibi4on of PKC Inhibits tyrosine kinases as well O Ima4nib (Glivec or Gleevec) Drug design Conformational! bloc...
View Full Document

This note was uploaded on 01/15/2014 for the course CHEM 167 taught by Professor Amaro during the Winter '13 term at UCSD.

Ask a homework question - tutors are online